Bronte Vincenzo, Mocellin Simone
Istituto Oncologico Veneto, Fondazione IRCCS, Padova, Italy.
J Immunother. 2009 Jan;32(1):1-11. doi: 10.1097/CJI.0b013e3181837276.
Although much evidence has been gathered demonstrating that immune effectors can play a significant role in controlling tumor growth under natural conditions or in response to therapeutic manipulation, it is clear that malignant cells do evade immune surveillance in most cases. Considering that anticancer active specific immunotherapy seems to have reached a plateau of results and that currently no vaccination regimen is indicated as a standard anticancer therapy, the dissection of the molecular events underlying tumor immune escape is the necessary condition to make anticancer vaccines a therapeutic weapon effective enough to be implemented in the routine clinical setting. Recent years have witnessed significant advances in our understanding of the molecular mechanisms underlying tumor immune escape. These mechanistic insights are fostering the development of rationally designed therapeutics aimed to revert the immunosuppressive circuits that undermine an effective antitumor immune response. In this review, the best characterized mechanisms that allow cancer cells to evade immune surveillance are overviewed and the most debated controversies constellating this complex field are highlighted.
尽管已有大量证据表明,免疫效应细胞在自然条件下或对治疗性操作作出反应时,能够在控制肿瘤生长方面发挥重要作用,但很明显,在大多数情况下恶性细胞确实会逃避免疫监视。鉴于抗癌活性特异性免疫疗法似乎已达到疗效瓶颈,且目前尚无疫苗接种方案被指定为标准抗癌疗法,剖析肿瘤免疫逃逸背后的分子事件是使抗癌疫苗成为一种足够有效的治疗武器并在常规临床环境中得以应用的必要条件。近年来,我们对肿瘤免疫逃逸背后分子机制的理解取得了重大进展。这些机制性见解正在推动合理设计的疗法的开发,旨在逆转破坏有效抗肿瘤免疫反应的免疫抑制回路。在本综述中,概述了癌细胞逃避免疫监视的最具特征的机制,并突出了构成这一复杂领域的最具争议的争论点。